Emerging Paradigms in Screening, Diagnosis, & Management of Lung Cancer

Lung cancer has the third-most incidence rate among all cancers in United States, yet it is the leading cause of cancer deaths. It is imperative to know more about this disease to understand it better so that we as a scientific community can discover novel treatments to treat it. Below is a slideshow showcasing the computational models I have constructed along with relevant information to display the recent trends in incidence, mortality, and survival rate of lung cancer in patients, innovations in treatment, and what research is yet to be done.

** If you would like to get into the nitty-gritty of the data analysis I have done, please feel free to explore the computational models shown below in the Google CoLaboratory environment by clicking here. **

References

1. American Cancer Society. Cancer.org. [accessed 2020 Oct 29]. http://cancerstatisticscenter.cancer.org/.

2. Cdc.gov. [accessed 2020 Oct 29]. http://gis.cdc.gov/Cancer/USCS/DataViz.html.

3. Cancerresearchuk.org. [accessed 2020 Oct 29]. https://www.cancerresearchuk.org/cancer-statistics/statistics-by-cancer-type/lung-cancer/risk-factors

4. Lung cancer signs & symptoms. Cancer.org. [accessed 2020 Oct 29]. https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/signs-symptoms.html

5. Non-small cell lung cancer treatment by stage. Cancer.org. [accessed 2020 Oct 29]. https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell/by-stage.html

6. DeVita VT Jr, Rosenberg SA, Lawrence TS. DeVita, Hellman, and Rosenberg’s cancer: Principles & practice of oncology. 11th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2018.

7. First-Line Treatment with Merck’s KEYTRUDA® (pembrolizumab) doubled five-year survival rate (31.9%) versus chemotherapy (16.3%) in certain patients with metastatic non-small cell lung cancer whose tumors express PD-L1 (TPS ≥50%) - Merck.Com. Merck.com. 2020 Sep 21 [accessed 2020 Oct 29]. https://www.merck.com/news/first-line-treatment-with-mercks-keytruda-pembrolizumab-doubled-five-year-survival-rate-31-9-versus-chemotherapy-16-3-in-certain-patients-with-metastatic-non-small-cell-lung-cance/